Hoth Therapeutics Stock Today

HOTH Stock  USD 0.81  0.04  4.71%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 8

 
High
 
Low
Low
Hoth Therapeutics is trading at 0.81 as of the 14th of December 2024. This is a 4.71 percent decrease since the beginning of the trading day. The stock's open price was 0.85. Hoth Therapeutics has only a 8 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 17th of June 2024 and ending today, the 14th of December 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
15th of February 2019
Category
Healthcare
Classification
Health Care
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York. Hoth Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 6.9 M outstanding shares of which 458.04 K shares are currently shorted by private and institutional investors with about 0.25 trading days to cover. More on Hoth Therapeutics

Moving against Hoth Stock

  0.55BMY Bristol Myers SquibbPairCorr
  0.53FLGC Flora Growth CorpPairCorr
  0.44ALVO AlvotechPairCorr
  0.32CAH Cardinal HealthPairCorr

Hoth Stock Highlights

President, FounderRobb Knie
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities641.9 K678.7 K
Notably Down
Slightly volatile
Non Current Liabilities Total25 K26.3 K
Notably Down
Slightly volatile
Total Assets5.8 M9.5 M
Way Down
Slightly volatile
Total Current Assets5.6 M9.4 M
Way Down
Slightly volatile
Debt Levels
Hoth Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Hoth Therapeutics' financial leverage. It provides some insight into what part of Hoth Therapeutics' total assets is financed by creditors.
Liquidity
Hoth Therapeutics currently holds 55.16 K in liabilities with Debt to Equity (D/E) ratio of 2.01, implying the company greatly relies on financing operations through barrowing. Hoth Therapeutics has a current ratio of 15.43, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Hoth Therapeutics' use of debt, we should always consider it together with its cash and equity.

Total Cashflows From Investing Activities

(156,260)
Hoth Therapeutics (HOTH) is traded on NASDAQ Exchange in USA. It is located in 590 Madison Avenue, New York, NY, United States, 10022 and employs 2 people. Hoth Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.59 M. Hoth Therapeutics conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 6.9 M outstanding shares of which 458.04 K shares are currently shorted by private and institutional investors with about 0.25 trading days to cover. Hoth Therapeutics currently holds about 11.62 M in cash with (8.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Hoth Therapeutics Probability Of Bankruptcy
Ownership Allocation
Roughly 93.78 (percent) of Hoth Therapeutics outstanding shares are held by general public with 0.92 % owned by insiders and only 5.3 pct. by outside corporations.
Check Hoth Ownership Details

Hoth Stock Institutional Holders

InstituionRecorded OnShares
Qube Research & Technologies2024-09-30
0.0
Armistice Capital, Llc2024-09-30
0.0
Hrt Financial Llc2024-09-30
121.9 K
Geode Capital Management, Llc2024-09-30
82.9 K
Ubs Group Ag2024-09-30
56.5 K
Vanguard Group Inc2024-09-30
38.8 K
Two Sigma Securities, Llc2024-09-30
18.6 K
Morgan Stanley - Brokerage Accounts2024-09-30
10.3 K
Tower Research Capital Llc2024-09-30
4.5 K
Royal Bank Of Canada2024-09-30
240
Bank Of America Corp2024-09-30
56.0
View Hoth Therapeutics Diagnostics

Hoth Therapeutics Historical Income Statement

As of now, Hoth Therapeutics' Research Development is increasing as compared to previous years. The Hoth Therapeutics' current Total Operating Expenses is estimated to increase to about 8.4 M, while Interest Income is projected to decrease to 741.95. View More Fundamentals

Hoth Stock Against Markets

Hoth Therapeutics Corporate Management

Jane SpringerVP OperationsProfile
Hayley SpringerExecutive OperationsProfile
Stefanie JohnsChief OfficerProfile
David BrionesChief OfficerProfile
When determining whether Hoth Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hoth Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hoth Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hoth Therapeutics Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hoth Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Hoth Stock please use our How to Invest in Hoth Therapeutics guide.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hoth Therapeutics. If investors know Hoth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hoth Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.27)
Return On Assets
(0.46)
Return On Equity
(0.83)
The market value of Hoth Therapeutics is measured differently than its book value, which is the value of Hoth that is recorded on the company's balance sheet. Investors also form their own opinion of Hoth Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Hoth Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hoth Therapeutics' market value can be influenced by many factors that don't directly affect Hoth Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hoth Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hoth Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hoth Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.